Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.42 |
| ▸ | SMO | Q99835 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1786445 | 0.89 | KDR (0.57) | KDRLMNAGAAMAPK1PTPN11 | |
| SCHEMBL1790457 | 0.88 | PTPN11 (0.45) | KDRLMNAPTPN11MAPTALDH1A1 | |
| SCHEMBL1791172 | 0.87 | MAPT (0.51) | KDRLMNAPTPN11MAPTALDH1A1 | |
| SCHEMBL1787272 | 0.82 | KDR (0.45) | KDRLMNAGAAMAPTRAB9A | |
| SCHEMBL1784588 | 0.80 | KDR (0.62) | KDRLMNAMAPTALDH1A1KDM4E | |
| SCHEMBL1787162 | 0.79 | ALDH1A1 (0.46) | KDRMAPTRAB9AALDH1A1KDM4E | |
| SCHEMBL1788671 | 0.79 | KDR (0.45) | KDRLMNAMAPTRAB9AALDH1A1 | |
| SCHEMBL1786747 | 0.79 | KDR (0.66) | KDRLMNAMAPTRAB9AALDH1A1 | |
| SCHEMBL1789859 | 0.79 | NPSR1 (0.49) | KDRPTPN11MAPTALDH1A1KDM4E | |
| SCHEMBL1786466 | 0.78 | KDR (0.59) | KDRLMNAMAPTRAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1864977-B1 | NOVEL CYCLIC COMPOUND HAVING PYRIMIDINYLALKYLTHIO GROUP | SANTEN PHARMACEUTICAL CO LTD (JP) | 2015-07-29 | — | — | EP | claimed |
| EP-1864977-B1 | NOVEL CYCLIC COMPOUND HAVING PYRIMIDINYLALKYLTHIO GROUP | SANTEN PHARMACEUTICAL CO LTD (JP) | 2015-07-29 | — | — | EP | disclosed |
| US-8507485-B2 | Cyclic compound having pyrimidinylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-20110124646-A1 | Novel cyclic compound having pyrimidinylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-05-26 | — | — | US | disclosed |
| US-7906511-B2 | Cyclic compound having pyrimidinylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-15 | — | — | US | disclosed |
| US-20090291951-A1 | Novel Cyclic Compound Having Pyrimidinylalkylthio Group | SATEN PHARMACEUTICAL CO., LTD. (JP) | 2009-11-26 | — | — | US | disclosed |
| EP-1864977-A1 | NOVEL CYCLIC COMPOUND HAVING PYRIMIDINYLALKYLTHIO GROUP | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291951-A1 | Novel Cyclic Compound Having Pyrimidinylalkylthio Group | AGTR1, AGTR2, ARRB1 | KDR 2531/4885LMNA 4680/4885GAA 2418/4885 |
| US-20110124646-A1 | Novel cyclic compound having pyrimidinylalkylthio group | FLT1, VEGFA, FLT4 | KDR 4/4885LMNA 4831/4885GAA 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.